Aktie A2DVJ4 SIENNA BIOPHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Sienna Biopharmaceuticals, Inc.

Aktien

A2DVJ4

US82622H1086

SNNAQ

Verzögert OTC Markets
Andere Börsenplätze
 19:22:47 25.03.2024 		% 5 Tage % 1. Jan.
0,000001 USD -.--% Intraday Chart für Sienna Biopharmaceuticals, Inc. -99,00 % -.--%
2019 Transcript : Sienna Biopharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03:55 PM
2019 Transcript : Sienna Biopharmaceuticals, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-09-2019 11:00 AM

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.
SIENNA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index
Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DVJ4 Aktie
  4. Nachrichten Sienna Biopharmaceuticals, Inc.
  5. Andere Sprachen